What the rescheduling of marijuana might — and might not — mean for scientific research Nicholas Florko Sarah Owermohle By Nicholas Florko and Sarah Owermohle May 30, 2024

https://www.statnews.com/2024/05/30/marijuana-rescheduling-impact-on-cannabis-research/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9PMHaUgmoKQwboi7BKbWthx2bonGNCng9bFr1RJMDtZsM3Wav_wX_BYfYbuRxiNUPiascoB7ZXtJ86MTAXoldpDtZEGQ&_hsmi=309321752&utm_content=309321752&utm_source=hs_email The Biden administration announced earlier this month that it intends to reclassify marijuana as a less dangerous drug and begin regulating it more like Schedule III drugs like anabolic steroids and ketamine. This would seem to open up new avenues for researchers who have been stymied by the federal government’s decades-old declaration that the drug is just as dangerous as heroin and LSD. But experts told STAT’s Nick Florko and Sarah Owermohle they have questions about what will come next for marijuana science. Will politics interfere with the process? What about the basic scientific information that we still don’t know about the substance? And will weed finally get cheaper? Read more from Nick and Sarah on what marijuana's reclassification might change (or not) for scientific research. https://www.statnews.com/2024/04/30/dea-reclassify-marijuana/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--IX7e-p47oiZOTu7aY1fvT0y83-Dw7nJNs11ONWmyw2NA9_Bz3BQWcLt14KTAHENut-Q-hplA9tdyP4r38i_A2al2Vnw&_hsmi=309321752&utm_content=309321752&utm_source=hs_email